Please ensure Javascript is enabled for purposes of website accessibility

Novavax Begins Early Stage Clinical Study of Its Coronavirus Vaccine Candidate

By Keith Speights – May 26, 2020 at 10:29AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech hopes to announce results from the phase 1 part of the clinical study in July.

Novavax (NVAX 2.20%) announced on Monday that it had begun enrolling participants in a phase 1/2 clinical trial of its coronavirus vaccine candidate NVX-CoV2373. The vaccine candidate demonstrated promising results in preclinical testing, including a significant immune system response and high levels of neutralizing antibodies, which bind to the novel coronavirus and block infection. 

About the study

The clinical study will consist of two parts. The phase 1 part of the study will evaluate the immunogenicity and safety of Novavax's COVID-19 vaccine candidate and will be conducted at two sites in Australia. Around 130 healthy participants between the ages of 18 and 59 are expected to be enrolled in the clinical trial. Two doses of the vaccine of either 5 or 25 micrograms will be given to participants in two randomized groups.

Healthcare professional holding syringe and vaccine bottle

Image source: Getty Images.

Novavax plans to conduct the phase 2 part of the clinical study in multiple countries, including the U.S. This portion of the study will evaluate the immunity, safety, and disease reduction provided by NVX-CoV2373 in a broader age range of participants.

The clinical trial is being funded by the Coalition for Epidemic Preparedness Innovations (CEPI). Novavax recently announced that CEPI was investing up to $384 million to fund the clinical development of NVX-CoV2373 in addition to its initial $4 million investment.

What's next

Novavax anticipates sharing preliminary immunogenicity and safety results from the phase 1 part of the clinical trial in July 2020. It those results are promising, the biotech will quickly advance its vaccine candidate into the phase 2 portion of the study. CEPI's investment in Novavax will enable the manufacturing of NVX-CoV2373 to be done in parallel with clinical testing.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$18.60 (2.20%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.